Health AI Central
Share:
Peer-Reviewed Publication
Mol Biomed2024;5(1):16.April 2, 2024Journal Article

Correction: annexin A5-DM1 protein-drug conjugate for the treatment of triple-negative breast cancer.

Alexis Woodward1, Benjamin Southard1, Sampurna Chakraborty1, Aaron O Bailey2,3, Gabriela N F Faria4, Patrick McKernan1, Wajeeha Razaq5, Roger G Harrison6,7
1Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA.
2Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
3AbCellera Biologics Inc, Vancouver, BC, Canada.
4School of Sustainable Chemical, Biological, and Materials Engineering, University of Oklahoma, Norman, OK, USA.
5Stephenson Cancer Center, Oklahoma City, OK, USA.
6School of Sustainable Chemical, Biological, and Materials Engineering, University of Oklahoma, Norman, OK, USA. rharrison@ou.edu.
7Stephenson Cancer Center, Oklahoma City, OK, USA. rharrison@ou.edu.
PubMed PMC DOI PDF

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.